Elixir
NAD+ learning · Published by Elixir

Three human studies, examined

This focused selection shows why molecule, route, population and outcome matter. It is not a systematic review or evidence that Elixir products work.

15 October 20262 min readUK adults 18+
Open research papers, a notebook and reading glasses.
AI-generated editorial image.

Read the study before the headline

The examples below were chosen to illustrate different research questions. They do not estimate an overall treatment effect or rank retail products. A download contains the same records for readers who want to make their own notes.

Download the study ledger (CSV)

StudyIngredient, route and participantsDesign and durationFinding within scopeLimits and interestsSource
Martens2018NR · Oral
Healthy adults aged 55–79; 30 randomised, 24 completed
Double-blind placebo-controlled crossover
Two six-week periods
NAD-related metabolism changed; exploratory findings require larger trialsSelected population, short follow-up, no formal washout; not evidence for other molecules/routes or longevity
Funding: NIH grants; ChromaDex supplied pills, standards and partial funding; authors declared no competing interests
Original paper
Yoshino2021NMN · Oral
25 overweight/obese postmenopausal women with prediabetes completed
Randomised placebo-controlled trial
Ten weeks
Muscle insulin sensitivity improved; several other outcomes did notSmall selected population; no general-population, other-route or Elixir product conclusion
Funding: Consult the original paper for full funding and conflicts; not independently extracted for this row
Original paper
Grant2019NAD+ · Intravenous infusion
11 healthy men; 8 NAD+, 3 saline
Small metabolism pilot with saline comparison
Six-hour infusion; eight-hour metabolite observation
Describes short-term metabolite changes, not sustained clinical efficacyVery small sample, short observation; not longevity or all-route safety evidence
Funding: Commercial author/provider interests disclosed; consult the original declarations
Original paper

Why these rows cannot be combined into a promise

The studies tested different interventions, populations and endpoints. A human biomarker result is different from a sustained clinical outcome. The IV pilot does not establish effects for another injection route; NR and NMN are not direct NAD+. None of these examples establishes an outcome for a finished Elixir product.

How this selection is maintained

Each row records the original source, ingredient, route, population, duration, endpoint and limitations. Sources were checked on 15 October 2026. Missing extraction details are stated rather than invented. This resource does not claim a clinician has reviewed it or that it contains every relevant study. A new paper should be appraised against the same fields before adding a row.

Use the detail responsibly

Consult the original methods, results and declarations. This selection omits study doses to avoid confusing a research intervention with consumer instructions. It is not personal advice or a recommendation to use a product.